What changed from existing technology?
This study used a type of artificial intelligence to find out which parts of a country's healthcare system most affect the survival of men with prostate cancer.
This is the first study to use interpretable machine learning to identify health system factors that influence prostate cancer survival outcomes at the country level.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
entifies health system levers for survival outcomes of patients with prostate cancer. Advances in the care of patients with prostate cancer across the disease
Title ↗agnosis, and access to timely diagnosis and treatment remain among the greatest across all malignancies. We aimed to quantify country-level health system
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This approach could help policymakers identify which aspects of healthcare systems need improvement to enhance prostate cancer survival outcomes globally.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.